New hope in fight against deadly brain cancer
NCT ID NCT06991101
Summary
This study is testing whether adding the drug ruxolitinib to the standard treatment (radiation plus temozolomide) works better for people newly diagnosed with glioblastoma, a serious type of brain cancer. About 190 adults will be randomly assigned to receive either the standard treatment alone or the standard treatment plus ruxolitinib. The main goal is to see if the combination helps people live longer compared to the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.